Karnezis AN, Cho KR, Gilks CB, Pearce CL, Huntsman DG. The disparate origins of ovarian cancers: pathogenesis and prevention strategies. Nat Rev Cancer. 2017;17(1):65–74.
Article
PubMed
CAS
Google Scholar
Colombo N, Sessa C, du Bois A, Ledermann J, McCluggage WG, McNeish I, Morice P, Pignata S, Ray-Coquard I, Vergote I, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent diseasedagger. Ann Oncol. 2019;30(5):672–705.
Article
PubMed
CAS
Google Scholar
Bhattacharya D, Scime A. Metabolic regulation of epithelial to mesenchymal transition: implications for endocrine cancer. Front Endocrinol (Lausanne). 2019;10:773.
Article
PubMed
Google Scholar
Evdokimova V, Tognon C, Ng T, Ruzanov P, Melnyk N, Fink D, Sorokin A, Ovchinnikov LP, Davicioni E, Triche TJ, et al. Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial–mesenchymal transition. Cancer Cell. 2009;15(5):402–15.
Article
PubMed
CAS
Google Scholar
Jolly MK, Ware KE, Gilja S, Somarelli JA, Levine H. EMT and MET: necessary or permissive for metastasis? Mol Oncol. 2017;11(7):755–69.
Article
PubMed
PubMed Central
Google Scholar
Klymenko Y, Kim O, Stack MS. Complex determinants of epithelial: mesenchymal phenotypic plasticity in ovarian cancer. Cancers (Basel). 2017;9(8):104.
Article
PubMed
Google Scholar
Ding Y, Pan Y, Liu S, Jiang F, Jiao J. Elevation of MiR-9-3p suppresses the epithelial–mesenchymal transition of nasopharyngeal carcinoma cells via down-regulating FN1, ITGB1 and ITGAV. Cancer Biol Ther. 2017;18(6):414–24.
Article
PubMed
PubMed Central
CAS
Google Scholar
Pastushenko I, Blanpain C. EMT transition states during tumor progression and metastasis. Trends Cell Biol. 2019;29(3):212–26.
Article
PubMed
CAS
Google Scholar
Panchy N, Azeredo-Tseng C, Luo M, Randall N, Hong T. Integrative transcriptomic analysis reveals a multiphasic epithelial–mesenchymal spectrum in cancer and non-tumorigenic cells. Front Oncol. 2019;9:1479.
Article
PubMed
Google Scholar
Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, Chen T, Roszik J, Bernatchez C, Woodman SE, et al. Loss of IFN-gamma pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell. 2016;167(2):397-404e9.
Article
PubMed
PubMed Central
CAS
Google Scholar
Latifi A, Abubaker K, Castrechini N, Ward AC, Liongue C, Dobill F, Kumar J, Thompson EW, Quinn MA, Findlay JK, et al. Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile. J Cell Biochem. 2011;112(10):2850–64.
Article
PubMed
CAS
Google Scholar
Ahmed N, Abubaker K, Findlay J, Quinn M. Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. Curr Cancer Drug Targets. 2010;10(3):268–78.
Article
PubMed
CAS
Google Scholar
Marchini S, Fruscio R, Clivio L, Beltrame L, Porcu L, Fuso Nerini I, Cavalieri D, Chiorino G, Cattoretti G, Mangioni C, et al. Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer. Eur J Cancer. 2013;49(2):520–30.
Article
PubMed
CAS
Google Scholar
Zhu J, Chen X, Liao Z, He C, Hu X. TGFBI protein high expression predicts poor prognosis in colorectal cancer patients. Int J Clin Exp Pathol. 2015;8(1):702–10.
PubMed
PubMed Central
Google Scholar
Zou J, Huang R, Li H, Wang B, Chen Y, Chen S, Ou K, Wang X. Secreted TGF-beta-induced protein promotes aggressive progression in bladder cancer cells. Cancer Manag Res. 2019;11:6995–7006.
Article
PubMed
PubMed Central
CAS
Google Scholar
Cheuk IW, Siu MT, Ho JC, Chen J, Shin VY, Kwong A. ITGAV targeting as a therapeutic approach for treatment of metastatic breast cancer. Am J Cancer Res. 2020;10(1):211–23.
PubMed
PubMed Central
CAS
Google Scholar
Ju HQ, Lu YX, Wu QN, Liu J, Zeng ZL, Mo HY, Chen Y, Tian T, Wang Y, Kang TB, et al. Disrupting G6PD-mediated Redox homeostasis enhances chemosensitivity in colorectal cancer. Oncogene. 2017;36(45):6282–92.
Article
PubMed
PubMed Central
CAS
Google Scholar
Bissey PA, Law JH, Bruce JP, Shi W, Renoult A, Chua MLK, Yip KW, Liu FF. Dysregulation of the MiR-449b target TGFBI alters the TGFbeta pathway to induce cisplatin resistance in nasopharyngeal carcinoma. Oncogenesis. 2018;7(5):40.
Article
PubMed
PubMed Central
Google Scholar
Ween MP, Oehler MK, Ricciardelli C. Transforming growth factor-beta-induced protein (TGFBI)/(betaig-H3): a matrix protein with dual functions in ovarian cancer. Int J Mol Sci. 2012;13(8):10461–77.
Article
PubMed
PubMed Central
CAS
Google Scholar
Goehrig D, Nigri J, Samain R, Wu Z, Cappello P, Gabiane G, Zhang X, Zhao Y, Kim IS, Chanal M, et al. Stromal protein betaig-h3 reprogrammes tumour microenvironment in pancreatic cancer. Gut. 2019;68(4):693–707.
Article
PubMed
CAS
Google Scholar
Steitz AM, Steffes A, Finkernagel F, Unger A, Sommerfeld L, Jansen JM, Wagner U, Graumann J, Muller R, Reinartz S. Tumor-associated macrophages promote ovarian cancer cell migration by secreting transforming growth factor beta induced (TGFBI) and tenascin C. Cell Death Dis. 2020;11(4):249.
Article
PubMed
PubMed Central
CAS
Google Scholar
Ween MP, Lokman NA, Hoffmann P, Rodgers RJ, Ricciardelli C, Oehler MK. Transforming growth factor-beta-induced protein secreted by peritoneal cells increases the metastatic potential of ovarian cancer cells. Int J Cancer. 2011;128(7):1570–84.
Article
PubMed
CAS
Google Scholar
Ricciardelli C, Lokman NA, Pyragius CE, Ween MP, Macpherson AM, Ruszkiewicz A, Hoffmann P, Oehler MK. Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance. Oncotarget. 2017;8(11):17819–32.
Article
PubMed
PubMed Central
Google Scholar
Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork P, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607–13.
Article
PubMed
CAS
Google Scholar
Gyorffy B, Lanczky A, Szallasi Z. Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr Relat Cancer. 2012;19(2):197–208.
Article
PubMed
CAS
Google Scholar
Al Ameri W, Ahmed I, Al-Dasim FM, Ali Mohamoud Y, Al-Azwani IK, Malek JA, Karedath T. Cell type-specific TGF-beta mediated EMT in 3D and 2D models and its reversal by TGF-beta receptor kinase inhibitor in ovarian cancer cell lines. Int J Mol Sci. 2019;20(14):3568.
Article
PubMed
PubMed Central
CAS
Google Scholar
Pike Winer LS, Wu M. Rapid analysis of glycolytic and oxidative substrate flux of cancer cells in a microplate. PLoS ONE. 2014;9(10): e109916.
Article
PubMed
PubMed Central
Google Scholar
Ricciardelli C, Lokman NA, Ween MP, Oehler MK. Women in cancer thematic review: ovarian cancer-peritoneal cell interactions promote extracellular matrix processing. Endocr Relat Cancer. 2016;23(11):T155–68.
Article
PubMed
CAS
Google Scholar
Shen DW, Pouliot LM, Hall MD, Gottesman MM. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev. 2012;64(3):706–21.
Article
PubMed
PubMed Central
CAS
Google Scholar
Pearson GW. Control of invasion by epithelial-to-mesenchymal transition programs during metastasis. J Clin Med. 2019;8(5):646.
Article
PubMed
PubMed Central
CAS
Google Scholar
Nieto MA, Cano A. The epithelial–mesenchymal transition under control: global programs to regulate epithelial plasticity. Semin Cancer Biol. 2012;22(5–6):361–8.
Article
PubMed
CAS
Google Scholar
Theveneau E, Mayor R. Cadherins in collective cell migration of mesenchymal cells. Curr Opin Cell Biol. 2012;24(5):677–84.
Article
PubMed
PubMed Central
CAS
Google Scholar
Collins NL, Reginato MJ, Paulus JK, Sgroi DC, Labaer J, Brugge JS. G1/S cell cycle arrest provides anoikis resistance through Erk-mediated Bim suppression. Mol Cell Biol. 2005;25(12):5282–91.
Article
PubMed
PubMed Central
CAS
Google Scholar
Braunstein S, Karpisheva K, Pola C, Goldberg J, Hochman T, Yee H, Cangiarella J, Arju R, Formenti SC, Schneider RJ. A hypoxia-controlled cap-dependent to cap-independent translation switch in breast cancer. Mol Cell. 2007;28(3):501–12.
Article
PubMed
CAS
Google Scholar
Frisch SM, Schaller M, Cieply B. Mechanisms that link the oncogenic epithelial–mesenchymal transition to suppression of anoikis. J Cell Sci. 2013;126(Pt 1):21–9.
Article
PubMed
PubMed Central
CAS
Google Scholar
Muller V, Stahmann N, Riethdorf S, Rau T, Zabel T, Goetz A, Janicke F, Pantel K. Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res. 2005;11(10):3678–85.
Article
PubMed
Google Scholar
Ahn A, Chatterjee A, Eccles MR. The slow cycling phenotype: a growing problem for treatment resistance in melanoma. Mol Cancer Ther. 2017;16(6):1002–9.
Article
PubMed
CAS
Google Scholar
Moore N, Houghton J, Lyle S. Slow-cycling therapy-resistant cancer cells. Stem Cells Dev. 2012;21(10):1822–30.
Article
PubMed
CAS
Google Scholar
Chen QK, Lee K, Radisky DC, Nelson CM. Extracellular matrix proteins regulate epithelial–mesenchymal transition in mammary epithelial cells. Differentiation. 2013;86(3):126–32.
Article
PubMed
PubMed Central
CAS
Google Scholar
Ahmed N, Riley C, Rice G, Quinn M. Role of integrin receptors for fibronectin, collagen and laminin in the regulation of ovarian carcinoma functions in response to a matrix microenvironment. Clin Exp Metastasis. 2005;22(5):391–402.
Article
PubMed
CAS
Google Scholar
Poltavets V, Kochetkova M, Pitson SM, Samuel MS. The role of the extracellular matrix and its molecular and cellular regulators in cancer cell plasticity. Front Oncol. 2018;8:431.
Article
PubMed
PubMed Central
Google Scholar
Gay O, Nakamura F, Baudier J. Refilin holds the cap. Commun Integr Biol. 2011;4(6):791–5.
Article
PubMed
PubMed Central
CAS
Google Scholar
Kumari A, Shonibare Z, Monavarian M, Arend RC, Lee NY, Inman GJ, Mythreye K. TGFbeta signaling networks in ovarian cancer progression and plasticity. Clin Exp Metastasis. 2021;38(2):139–61.
Article
PubMed
PubMed Central
Google Scholar
Foroutan M, Cursons J, Hediyeh-Zadeh S, Thompson EW, Davis MJ. A Transcriptional Program for Detecting TGFbeta-Induced EMT in Cancer. Mol Cancer Res. 2017;15(5):619–31.
Article
PubMed
CAS
Google Scholar
Wang N, Zhang H, Yao Q, Wang Y, Dai S, Yang X. TGFBI promoter hypermethylation correlating with paclitaxel chemoresistance in ovarian cancer. J Exp Clin Cancer Res. 2012;31:6.
Article
PubMed
PubMed Central
Google Scholar
Ahmed AA, Mills AD, Ibrahim AE, Temple J, Blenkiron C, Vias M, Massie CE, Iyer NG, McGeoch A, Crawford R, et al. The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel. Cancer Cell. 2007;12(6):514–27.
Article
PubMed
PubMed Central
CAS
Google Scholar
Januchowski R, Zawierucha P, Rucinski M, Zabel M. Microarray-based detection and expression analysis of extracellular matrix proteins in drugresistant ovarian cancer cell lines. Oncol Rep. 2014;32(5):1981–90.
Article
PubMed
CAS
Google Scholar
Gharibi A, La Kim S, Molnar J, Brambilla D, Adamian Y, Hoover M, Hong J, Lin J, Wolfenden L, Kelber JA. ITGA1 is a pre-malignant biomarker that promotes therapy resistance and metastatic potential in pancreatic cancer. Sci Rep. 2017;7(1):10060.
Article
PubMed
PubMed Central
Google Scholar
Huang W, Zhu J, Shi H, Wu Q, Zhang C. ITGA2 overexpression promotes esophageal squamous cell carcinoma aggression via FAK/AKT signaling pathway. Onco Targets Ther. 2021;14:3583–96.
Article
PubMed
PubMed Central
Google Scholar
Wang Q, Cao T, Guo K, Zhou Y, Liu H, Pan Y, Hou Q, Nie Y, Fan D, Lu Y, et al. Regulation of Integrin Subunit Alpha 2 by miR-135b-5p Modulates Chemoresistance in Gastric Cancer. Front Oncol. 2020;10:308.
Article
PubMed
PubMed Central
Google Scholar
Zhang KR, Zhang YF, Lei HM, Tang YB, Ma CS, Lv QM, Wang SY, Lu LM, Shen Y, Chen HZ, et al. Targeting AKR1B1 inhibits glutathione de novo synthesis to overcome acquired resistance to EGFR-targeted therapy in lung cancer. Sci Transl Med. 2021;13(614):eabg6428.
Article
PubMed
CAS
Google Scholar
Schwab A, Siddiqui A, Vazakidou ME, Napoli F, Bottcher M, Menchicchi B, Raza U, Saatci O, Krebs AM, Ferrazzi F, et al. Polyol pathway links glucose metabolism to the aggressiveness of cancer cells. Cancer Res. 2018;78(7):1604–18.
Article
PubMed
CAS
Google Scholar
Wang Q, Karvelsson ST, Kotronoulas A, Gudjonsson T, Halldorsson S, Rolfsson O. Glutamine-fructose-6-phosphate transaminase 2 (GFPT2) Is upregulated in breast epithelial–mesenchymal transition and responds to oxidative stress. Mol Cell Proteomics. 2022;21(2): 100185.
Article
PubMed
CAS
Google Scholar
Wang BJ, Chi KP, Shen RL, Zheng SW, Guo Y, Li JF, Fei J, He Y. TGFBI promotes tumor growth and is associated with poor prognosis in oral squamous cell carcinoma. J Cancer. 2019;10(20):4902–12.
Article
PubMed
PubMed Central
CAS
Google Scholar
Jeng W, Loniewska MM, Wells PG. Brain glucose-6-phosphate dehydrogenase protects against endogenous oxidative DNA damage and neurodegeneration in aged mice. ACS Chem Neurosci. 2013;4(7):1123–32.
Article
PubMed
PubMed Central
CAS
Google Scholar
Kleih M, Bopple K, Dong M, Gaissler A, Heine S, Olayioye MA, Aulitzky WE, Essmann F. Direct impact of cisplatin on mitochondria induces ROS production that dictates cell fate of ovarian cancer cells. Cell Death Dis. 2019;10(11):851.
Article
PubMed
PubMed Central
Google Scholar
Yamawaki K, Mori Y, Sakai H, Kanda Y, Shiokawa D, Ueda H, Ishiguro T, Yoshihara K, Nagasaka K, Onda T, et al. Integrative analyses of gene expression and chemosensitivity of patient-derived ovarian cancer spheroids link G6PD-driven redox metabolism to cisplatin chemoresistance. Cancer Lett. 2021;521:29–38.
Article
PubMed
CAS
Google Scholar
Gentric G, Kieffer Y, Mieulet V, Goundiam O, Bonneau C, Nemati F, Hurbain I, Raposo G, Popova T, Stern MH, et al. PML-regulated mitochondrial metabolism enhances chemosensitivity in human ovarian cancers. Cell Metab. 2019;29(1):156-173 e110.
Article
PubMed
PubMed Central
CAS
Google Scholar
Saed GM, Diamond MP, Fletcher NM. Updates of the role of oxidative stress in the pathogenesis of ovarian cancer. Gynecol Oncol. 2017;145(3):595–602.
Article
PubMed
CAS
Google Scholar
Acland M, Lokman NA, Young C, Anderson D, Condina M, Desire C, Noye TM, Wang W, Ricciardelli C, Creek DJ, et al. Chemoresistant cancer cell lines are characterized by migratory, amino acid metabolism, protein catabolism and IFN1 signalling perturbations. Cancers (Basel). 2022;14(11):2763.
Article
PubMed
CAS
Google Scholar
Terry S, Savagner P, Ortiz-Cuaran S, Mahjoubi L, Saintigny P, Thiery JP, Chouaib S. New insights into the role of EMT in tumor immune escape. Mol Oncol. 2017;11(7):824–46.
Article
PubMed
PubMed Central
Google Scholar
Akalay I, Janji B, Hasmim M, Noman MZ, Andre F, De Cremoux P, Bertheau P, Badoual C, Vielh P, Larsen AK, et al. Epithelial-to-mesenchymal transition and autophagy induction in breast carcinoma promote escape from T-cell-mediated lysis. Cancer Res. 2013;73(8):2418–27.
Article
PubMed
CAS
Google Scholar
Chen Y, Zhao H, Feng Y, Ye Q, Hu J, Guo Y, Feng Y. Pan-cancer analysis of the associations of TGFBI expression with prognosis and immune characteristics. Front Mol Biosci. 2021;8: 745649.
Article
PubMed
PubMed Central
CAS
Google Scholar
Ghisoni E, Imbimbo M, Zimmermann S, Valabrega G. Ovarian cancer immunotherapy: turning up the heat. Int J Mol Sci. 2019;20(12):2927.
Article
PubMed
PubMed Central
CAS
Google Scholar
Awada A, Ahmad S, McKenzie ND, Holloway RW. Immunotherapy in the treatment of platinum-resistant ovarian cancer: current perspectives. Onco Targets Ther. 2022;15:853–66.
Article
PubMed
PubMed Central
Google Scholar
Leary A, Tan D, Ledermann J. Immune checkpoint inhibitors in ovarian cancer: where do we stand? Ther Adv Med Oncol. 2021;13:17588359211039900.
Article
PubMed
PubMed Central
CAS
Google Scholar
Ahmed N, Escalona R, Leung D, Chan E, Kannourakis G. Tumour microenvironment and metabolic plasticity in cancer and cancer stem cells: Perspectives on metabolic and immune regulatory signatures in chemoresistant ovarian cancer stem cells. Semin Cancer Biol. 2018;53:265–81.
Article
PubMed
CAS
Google Scholar